SAB Biotherapeutics, Inc. (SABS) DCF Valuation

SAB Biotherapeutics, Inc. (SABS) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

SAB Biotherapeutics, Inc. (SABS) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Explore the financial outlook of SAB Biotherapeutics, Inc. (SABS) using our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to calculate the intrinsic value of SAB Biotherapeutics, Inc. (SABS) and inform your investment decisions.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 3.4 55.2 60.9 23.9 2.2 2.0 1.8 1.6 1.5 1.3
Revenue Growth, % 0 1504.91 10.21 -60.73 -90.63 -10.29 -10.29 -10.29 -10.29 -10.29
EBITDA -8.2 21.1 -15.2 -15.1 -38.1 -1.0 -.9 -.8 -.7 -.7
EBITDA, % -239.25 38.26 -24.96 -63.26 -1700.56 -49.99 -49.99 -49.99 -49.99 -49.99
Depreciation .3 .5 1.7 3.3 3.7 .5 .5 .4 .4 .3
Depreciation, % 9.4 0.9924 2.72 13.77 167.28 25.38 25.38 25.38 25.38 25.38
EBIT -8.6 20.6 -16.9 -18.4 -41.8 -1.1 -1.0 -.9 -.8 -.7
EBIT, % -248.64 37.27 -27.68 -77.03 -1867.83 -53.49 -53.49 -53.49 -53.49 -53.49
Total Cash 6.3 12.6 33.2 15.0 56.6 1.4 1.2 1.1 1.0 .9
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 2.8 20.6 8.0 5.6 .0
Account Receivables, % 81.9 37.24 13.16 23.25 0
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 0 0 0 0 0 0 0 0 0 0
Accounts Payable 2.2 7.4 4.5 3.7 .9 .6 .5 .5 .4 .4
Accounts Payable, % 63.07 13.36 7.32 15.39 42.25 28.28 28.28 28.28 28.28 28.28
Capital Expenditure -.6 -12.7 -10.9 -10.9 -.2 -.5 -.4 -.4 -.3 -.3
Capital Expenditure, % -17.69 -23.05 -17.98 -45.78 -8.81 -22.66 -22.66 -22.66 -22.66 -22.66
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -9.0 20.6 -17.1 -18.4 -41.8 -1.1 -1.0 -.9 -.8 -.7
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -9.9 -4.1 -16.8 -24.4 -35.4 -2.0 -.9 -.8 -.7 -.7
WACC, % 7.04 7.04 7.04 7.04 7.04 7.04 7.04 7.04 7.04 7.04
PV UFCF
SUM PV UFCF -4.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -1
Terminal Value -13
Present Terminal Value -9
Enterprise Value -14
Net Debt -51
Equity Value 37
Diluted Shares Outstanding, MM 6
Equity Value Per Share 6.67

What You Will Get

  • Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real SABS financials.
  • Real-World Data: Historical data and forward-looking estimates (as indicated in the highlighted cells).
  • Forecast Flexibility: Modify forecast assumptions such as revenue growth, EBITDA %, and WACC.
  • Automatic Calculations: Instantly observe how your inputs affect SAB Biotherapeutics' valuation.
  • Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
  • User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.

Key Features

  • Comprehensive Data: SAB Biotherapeutics’ historical financial statements and detailed forecasts.
  • Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Insights: Observe the recalculation of SAB Biotherapeutics’ intrinsic value instantly.
  • Intuitive Visual Displays: Dashboard charts present valuation results and essential metrics clearly.
  • Designed for Precision: A robust tool tailored for analysts, investors, and finance professionals.

How It Works

  • 1. Access the Template: Download and open the Excel file containing SAB Biotherapeutics, Inc.'s preloaded data.
  • 2. Modify Assumptions: Adjust key parameters such as growth rates, WACC, and capital expenditures.
  • 3. View Results Instantly: The DCF model automatically computes the intrinsic value and NPV.
  • 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation results.
  • 5. Present with Assurance: Deliver professional valuation insights to back your decisions.

Why Choose This Calculator for SAB Biotherapeutics, Inc. (SABS)?

  • Designed for Experts: A sophisticated tool tailored for researchers, investors, and industry leaders.
  • Comprehensive Data: SAB Biotherapeutics' historical and projected financials integrated for precise analysis.
  • Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
  • Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
  • User-Friendly: Detailed instructions walk you through each step of the calculation.

Who Should Use This Product?

  • Investors: Evaluate SAB Biotherapeutics' valuation before making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation methodologies and assess future projections.
  • Startup Founders: Understand the valuation strategies of leading biotech firms like SAB Biotherapeutics.
  • Consultants: Create detailed valuation reports for clients in the biotech sector.
  • Students and Educators: Utilize real-world examples to learn and teach valuation practices.

What the Template Contains

  • Historical Data: Includes SAB Biotherapeutics' past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate SAB Biotherapeutics' intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of SAB Biotherapeutics' financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

Es wurden keine passenden Produkte gefunden.